{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:29:00Z","timestamp":1788866940851,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032767","name":"Sichuan Medical Association","doi-asserted-by":"crossref","award":["Q2024042"],"award-info":[{"award-number":["Q2024042"]}],"id":[{"id":"10.13039\/100032767","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47397-7","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:49:24Z","timestamp":1775490564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors, prognostic impact, and antimicrobial susceptibility profiles of carbapenem-resistant Acinetobacter baumannii bloodstream infections: a retrospective cohort study"],"prefix":"10.1038","volume":"16","author":[{"given":"Ningjing","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"10","key":"47397_CR1","doi-asserted-by":"publisher","first-page":"ofaa378","DOI":"10.1093\/ofid\/ofaa378","volume":"7","author":"HJ Son","year":"2020","unstructured":"Son, H. J. et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Open. Forum Infect. Dis. 7 (10), ofaa378 (2020).","journal-title":"Open. Forum Infect. Dis."},{"issue":"4","key":"47397_CR2","doi-asserted-by":"publisher","first-page":"dlab157","DOI":"10.1093\/jacamr\/dlab157","volume":"3","author":"W Ling","year":"2021","unstructured":"Ling, W., Furuya-Kanamori, L., Ezure, Y., Harris, P. N. A. & Paterson, D. L. Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis. JAC Antimicrob. Resist. 3 (4), dlab157 (2021).","journal-title":"JAC Antimicrob. Resist."},{"issue":"9","key":"47397_CR3","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","volume":"47","author":"X Du","year":"2019","unstructured":"Du, X. et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. Am. J. Infect. Control. 47 (9), 1140\u20131145 (2019).","journal-title":"Am. J. Infect. Control"},{"key":"47397_CR4","doi-asserted-by":"publisher","first-page":"1549940","DOI":"10.3389\/fcimb.2025.1549940","volume":"15","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Exploring the clinical outcomes and molecular characteristics of Acinetobacter baumannii bloodstream infections: a study of sequence types, capsular types, and drug resistance in China. Front. Cell. Infect. Microbiol. 15, 1549940 (2025).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"6","key":"47397_CR5","first-page":"661","volume":"24","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. CHINET surveillance of antimicrobial resistance among clinical isolates in China in 2023. Chin. J. Infect. Chemother. 24 (6), 661\u2013671 (2024). [Article in Chinese].","journal-title":"Chin. J. Infect. Chemother."},{"issue":"2","key":"47397_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","volume":"79","author":"A Russo","year":"2019","unstructured":"Russo, A. et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. J. Infect. 79 (2), 130\u2013138 (2019).","journal-title":"J. Infect."},{"issue":"3","key":"47397_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18 (3), 318\u2013327 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"47397_CR8","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 33rd ed. CLSI guideline M100. Wayne, PA: CLSI, (2023)."},{"issue":"1","key":"47397_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji, B. T. et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 39 (1), 10\u201339 (2019).","journal-title":"Pharmacotherapy"},{"key":"47397_CR10","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2 (1), 1\u2013138 (2012)."},{"key":"47397_CR11","unstructured":"Centers for Disease Control and Prevention. NHSN patient safety component manual: BSI Event (U.S. Department of Health and Human Services, 2024)."},{"key":"47397_CR12","unstructured":"European Committee on Antimicrobial Susceptibility Testing. EUCAST Breakpoint Tables for Interpretation of MICs and Zone Diameters. (2024). Version 14.0."},{"issue":"1","key":"47397_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld, D. Partial residuals for the proportional hazards regression model. Biometrika 69 (1), 239\u2013241 (1982).","journal-title":"Biometrika"},{"issue":"1","key":"47397_CR14","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1080\/22221751.2022.2093134","volume":"11","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units (ICUs) in China. Emerg. Microbes Infect. 11 (1), 1730\u20131741 (2022).","journal-title":"Emerg. Microbes Infect."},{"issue":"6","key":"47397_CR15","doi-asserted-by":"publisher","first-page":"e0226023","DOI":"10.1128\/mbio.02260-23","volume":"14","author":"C M\u00fcller","year":"2023","unstructured":"M\u00fcller, C. et al. A global view on carbapenem-resistant Acinetobacter baumannii. mBio 14 (6), e0226023 (2023).","journal-title":"mBio"},{"issue":"12","key":"47397_CR16","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.ajic.2013.04.003","volume":"41","author":"Y Fukuta","year":"2013","unstructured":"Fukuta, Y. et al. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am. J. Infect. Control. 41 (12), 1249\u20131252 (2013).","journal-title":"Am. J. Infect. Control"},{"issue":"1","key":"47397_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","volume":"30","author":"D Wong","year":"2017","unstructured":"Wong, D. et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin. Microbiol. Rev. 30 (1), 409\u2013447 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"47397_CR18","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3389\/fmicb.2019.01601","volume":"10","author":"FC Morris","year":"2019","unstructured":"Morris, F. C., Dexter, C., Kostoulias, X., Uddin, M. I. & Peleg, A. Y. The mechanisms of disease caused by Acinetobacter baumannii. Front. Microbiol. 10, 1601 (2019).","journal-title":"Front. Microbiol."},{"issue":"1","key":"47397_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13054-016-1392-4","volume":"20","author":"MD Zilberberg","year":"2016","unstructured":"Zilberberg, M. D., Nathanson, B. H., Sulham, K., Fan, W. & Shorr, A. F. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit. Care. 20 (1), 221 (2016).","journal-title":"Crit. Care"},{"issue":"2","key":"47397_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","volume":"15","author":"RL Nation","year":"2015","unstructured":"Nation, R. L. et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect. Dis. 15 (2), 225\u2013234 (2015).","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"47397_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jmii.2014.10.006","volume":"49","author":"CP Liu","year":"2016","unstructured":"Liu, C. P. et al. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J. Microbiol. Immunol. Infect. 49 (6), 934\u2013940 (2016).","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"1","key":"47397_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1186\/s12879-021-06719-y","volume":"21","author":"GL Xia","year":"2021","unstructured":"Xia, G. L. & Jiang, R. L. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections. BMC Infect. Dis. 21 (1), 1034 (2021).","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"47397_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","volume":"47","author":"W Ni","year":"2016","unstructured":"Ni, W. et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int. J. Antimicrob. Agents. 47 (2), 107\u2013116 (2016).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"47397_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bjid.2012.10.029","volume":"17","author":"H Chu","year":"2013","unstructured":"Chu, H. et al. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J. Infect. Dis. 17 (4), 389\u2013394 (2013).","journal-title":"Braz J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47397-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47397-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47397-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:52:40Z","timestamp":1782316360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47397-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47397"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47397-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In the original version of this Article the authors' affiliation was incorrectly stated as 'Department of Clinical Laboratory, The Third People\u2019s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, China.' The correct affiliation is 'Department of Clinical Laboratory, Affiliated Hospital of Southwest Jiaotong University, The Third People\u2019s Hospital of Chengdu, Chengdu, Sichuan, China.' The original Article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethics Committee of The Third People\u2019s Hospital of Chengdu (Approval No.: 2024-S-382) and complies with the ethical principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"16481"}}